1
|
Zeng J, Zhang W, Lu X, Zhou H, Huang J, Xu Z, Liao H, Liang J, Liang M, Ye C, Sun T, Hu Y, She Q, Chen H, Guo Q, Yan L, Wu R, Li Z. The association of SOD and HsCRP with the efficacy of sulforaphane in schizophrenia patients with residual negative symptoms. Eur Arch Psychiatry Clin Neurosci 2023:10.1007/s00406-023-01679-7. [PMID: 37728803 DOI: 10.1007/s00406-023-01679-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Accepted: 08/08/2023] [Indexed: 09/21/2023]
Abstract
OBJECTIVES Emerging evidence indicates a connection between oxidative stress, immune-inflammatory processes, and the negative symptoms of schizophrenia. In addition to possessing potent antioxidant and anti-inflammatory properties, sulforaphane (SFN) has shown promise in enhancing cognitive function among individuals with schizophrenia. This study aims to investigate the efficacy of combined treatment with SFN in patients with schizophrenia who experience negative symptoms and its effect on the levels of superoxide dismutase (SOD) and the inflammatory marker, high-sensitivity C-reactive protein (HsCRP). DESIGN Forty-five patients with schizophrenia were recruited, who mainly experienced negative symptoms during a stable period. In addition to the original treatments, the patients received SFN tablets at a daily dose of 90 mg for 24 weeks. At baseline, 12 weeks, and 24 weeks, the participants were interviewed and evaluated. The reduction rate of the Positive and Negative Syndrome Scale (PANSS) was used to assess each participant. The side effects scale of Treatment Emergent Symptom Scale (TESS) was applied to assess the adverse reactions. Additionally, the levels of the SOD, HsCRP, and other indicators were examined. RESULTS The study findings revealed a significant decrease in PANSS negative subscale scores (P < 0.001). Furthermore, there was a significant increase in SOD activity and HsCRP levels (P < 0.001 and P < 0.05). Notably, the group of participants who exhibited a reduction in PANSS negative subscale scores demonstrated a significant improvement in HsCRP levels (P < 0.05). CONCLUSIONS Our study suggests that SFN may potentially serve as a safe adjunctive intervention to improve the negative symptoms of schizophrenia. The potential mechanism by which SFN improves negative symptoms in schizophrenia patients may involve its anti-inflammatory properties, specifically its ability to reduce HsCRP levels. Trial registration ClinicalTrial.gov (ID: NCT03451734).
Collapse
Affiliation(s)
- Jianfei Zeng
- Department of Nutritional and Metabolic Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Mingxin Road #36, Liwan District, Guangzhou, 510370, China
- Shenzhen Mental Health Center/Shenzhen Kangning Hospital, Shenzhen, China
| | - Weizhi Zhang
- Department of Nutritional and Metabolic Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Mingxin Road #36, Liwan District, Guangzhou, 510370, China
| | - Xiaobing Lu
- Department of Nutritional and Metabolic Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Mingxin Road #36, Liwan District, Guangzhou, 510370, China.
- Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China.
| | - Hui Zhou
- Shiyan People's Hospital of Baoan District, Shenzhen, China
| | - Jing Huang
- Department of Psychiatry, National Clinical Research Center for Mental Diseases, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Zhenyu Xu
- Ganzhou People's Hospital of Jiangxi Province, Ganzhou, China
| | - Hairong Liao
- The Third People's Hospital of Foshan, Foshan, China
| | - Jiaquan Liang
- The Third People's Hospital of Foshan, Foshan, China
| | - Meihong Liang
- The Third People's Hospital of Foshan, Foshan, China
| | - Chan Ye
- University of Chinese Academy of Science-Shenzhen Hospital, Shenzhen, China
| | - Ting Sun
- Zhuhai Center for Chronic Disease Control/The Third People's Hospital of Zhuhai, Zhuhai, China
| | - Yutong Hu
- Zhuhai Center for Chronic Disease Control/The Third People's Hospital of Zhuhai, Zhuhai, China
| | - Qi She
- Zhuhai Center for Chronic Disease Control/The Third People's Hospital of Zhuhai, Zhuhai, China
| | - Haixia Chen
- Zhongshan Third People's Hospital, Zhongshan, China
| | - Qian Guo
- Zhaoqing Third People's Hospital, Zhaoqing, China
| | - LiuJiao Yan
- Department of Nutritional and Metabolic Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Mingxin Road #36, Liwan District, Guangzhou, 510370, China
- Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China
| | - Renrong Wu
- Department of Psychiatry, National Clinical Research Center for Mental Diseases, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Zezhi Li
- Department of Nutritional and Metabolic Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Mingxin Road #36, Liwan District, Guangzhou, 510370, China.
- Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China.
- Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University, Guangzhou, China.
- Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing, China.
| |
Collapse
|